201 results on '"Ieko, M."'
Search Results
2. Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases
3. Rapid remission of severe pain from livedoid vasculopathy by apixaban
4. APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica‐based reagent
5. The production of coagulation factor VII by adipocytes is enhanced by tumor necrosis factor-α or isoproterenol
6. Index of circulating anticoagulant cut-off value establishment in activated partial thromboplastin time mixing test for lupus anticoagulant diagnosis
7. The inhibition of protein C anticoagulant activity by anti-β2-glycoprotein I (β2GPI) antibodies isolated from patients with antiphospholipid syndrome by chromatography methods
8. Trousseau’s syndrome associated with tissue factor produced by pulmonary adenocarcinoma
9. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis
10. Protection by alpha 2-macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor-1
11. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome
12. ?2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies
13. Large scale purification of human blood CD34+ cells using a nylon-fiber syringe system and immunomagnetic microspheres
14. Rapid remission of severe pain from livedoid vasculopathy by apixaban
15. Protection by α2‐macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor‐1
16. The production of coagulation factor VII by adipocytes is enhanced by tumor necrosis factor-α or isoproterenol
17. The influence of beta2-glycoprotein I on tissue factor activity
18. Haemophagocytic syndrome in a patient with dermatomyositis
19. The inhibition of protein C anticoagulant activity by anti-β 2 -glycoprotein I (β 2 GPI) antibodies isolated from patients with antiphospholipid syndrome by chromatography methods
20. Multiple thromboses in major arteries in a patient with antiphospholipid syndrome associated with excess of a large multimer of von Willebrand factor
21. Large scale purification of human blood CD34+ cells using a nylon-fiber syringe system and immunomagnetic microspheres
22. Subclinical Alterations in Coagulation and Fibrinolysis in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation
23. Protection by α2‐macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor‐1
24. Role of cytokines in leukemic type growth of myelodysplastic CD34+ cells
25. In vitro expansion of human peripheral blood CD34+ cells
26. Proliferation and differentiation of myelodysplastic CD34+cells in serum-free medium: response to individual colony-stimulating factors
27. Transitional change of colony stimulating factor requirements for erythroid progenitors
28. Purification of human marrow progenitor cells and demonstration of the direct action of macrophage colony-stimulating factor on colony-forming unit-macrophage
29. The inhibition of protein C anticoagulant activity by anti-β2-glycoprotein I (β2GPI) antibodies isolated from patients with antiphospholipid syndrome by chromatography methods.
30. Large Scale Purification of Human Blood CD34 + Cells Using a Nylon-fiber Syringe System and Immunomagnetic Microspheres.
31. Proliferation and differentiation of myelodysplastic CD34+ cells in serum-free medium: response to individual colony-stimulating factors.
32. Significance of fully automated tests for the diagnosis of antiphospholipid syndrome
33. Role of physiologic concentrations of stem cell factor in leukemic type growth of myelodysplastic CD34^+ cells
34. Protection by alpha2-macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor-1
35. Multiple thromboses in major arteries in a patient with antiphospholipid syndrome associated with excess of large multimer of von Willebrand factor.
36. Letter to the editor. Haemophagocytic syndrome in a patient with dermatomyositis.
37. Treatment of thrombotic cardiovascular diseases in people with haemophilia: A Japanese consensus study.
38. Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants.
39. Investigation of real-world heparin resistance and anticoagulation management prior to cardiopulmonary bypass: report from a nationwide survey by the Japanese Association for Thoracic Surgery heparin resistance working group.
40. Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents.
41. [Suspected autoimmune coagulation factor IX deficiency difficult to diagnose due to concurrent lupus anticoagulant].
42. Prevention of venous thromboembolism in pregnant women with congenital antithrombin deficiency: a retrospective study of a candidate protocol.
43. Lupus anticoagulant-hypoproaccelerin (factor V) syndrome (LAHPS-V): a new hemorrhagic condition associated with lupus anticoagulant.
44. Determination of diagnostic threshold in harmonization and comparison of clinical utility for five major antiphospholipid antibody assays used in Japan.
45. Bleeding After Gastric Endoscopic Submucosal Dissection Focused on Management of Xa Inhibitors.
46. Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy.
47. Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan.
48. International Council for Standardization in Haematology (ICSH) laboratory guidance for the verification of haemostasis analyser-reagent test systems. Part 2: Specialist tests and calibrated assays.
49. Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis.
50. International Council for Standardization in Haematology (ICSH) laboratory guidance for the evaluation of haemostasis analyser-reagent test systems. Part 1: Instrument-specific issues and commonly used coagulation screening tests.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.